Accelerated middle half body radiotherapy in bone metastases from prostate cancer: A phase I study (SHARON project)

Alice Zamagni; Milly Buwenge; Gabriella Macchia; Giambattista Siepe; Savino Cilla; Francesco Cellini; Alessandra Arcelli; Eleonora Farina; Francesco Deodato; Silvia Cammelli; Alessio G. Morganti; Alessio Giuseppe Morganti

doi:10.21873/anticanres.13699

Accelerated middle half body radiotherapy in bone metastases from prostate cancer: A phase I study (SHARON project)

Alice Zamagni, Milly Buwenge, Gabriella Macchia, Giambattista Siepe, Savino Cilla, Francesco Cellini, Alessandra Arcelli, Eleonora Farina, Francesco Deodato, Silvia Cammelli, Alessio G. Morganti, Alessio Giuseppe Morganti

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

Background/Aim: The primary endpoint of this phase I study was the maximum tolerated dose (MTD) of middle half body (MHB) accelerated radiotherapy (RT) in multiple bone metastatic (BM) prostate cancer (PCa) patients. Patients and Methods: Three step dose escalation [13 Gy (3.25 Gy/fraction), 14 Gy (3.5 Gy/fraction), and 15 Gy (3.75 Gy/fraction)] in three consecutive patient cohorts were planned. RT was delivered in two consecutive days and two daily fractions. Six patients were enrolled in the first two cohorts and 12 in the third cohort. Grade ≥3 toxicity was considered as a dose-limiting toxicity (DLT). Results: Twenty-five patients (median age=71 years, median followup=7.4 months) were enrolled. Defined MTD dose was 15 Gy. Overall pain response rate was 76%: 9 patients (36%) showed complete and 10 patients (40%) reported partial response of pain. Conclusion: MHB accelerated RT (total dose: 15 Gy) delivered in two consecutive days and two daily fractions is well tolerated.

Lingua originale	English
pagine (da-a)	5065-5069
Numero di pagine	5
Rivista	Anticancer Research
Volume	39
DOI	https://doi.org/10.21873/anticanres.13699
Stato di pubblicazione	Pubblicato - 2019

Keywords

Aged
Bone Neoplasms
Bone metastases
Combined Modality Therapy
Follow-Up Studies
Humans
Male
Maximum Tolerated Dose
Middle Aged
Palliative therapy
Phase I
Prostate neoplasm
Prostatic Neoplasms
Quality of Life
Radiotherapy
Radiotherapy Dosage
Treatment Outcome

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.21873/anticanres.13699

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{b53e772e603d41118c8e6fd8de893770,

title = "Accelerated middle half body radiotherapy in bone metastases from prostate cancer: A phase I study (SHARON project)",

abstract = "Background/Aim: The primary endpoint of this phase I study was the maximum tolerated dose (MTD) of middle half body (MHB) accelerated radiotherapy (RT) in multiple bone metastatic (BM) prostate cancer (PCa) patients. Patients and Methods: Three step dose escalation [13 Gy (3.25 Gy/fraction), 14 Gy (3.5 Gy/fraction), and 15 Gy (3.75 Gy/fraction)] in three consecutive patient cohorts were planned. RT was delivered in two consecutive days and two daily fractions. Six patients were enrolled in the first two cohorts and 12 in the third cohort. Grade ≥3 toxicity was considered as a dose-limiting toxicity (DLT). Results: Twenty-five patients (median age=71 years, median followup=7.4 months) were enrolled. Defined MTD dose was 15 Gy. Overall pain response rate was 76%: 9 patients (36%) showed complete and 10 patients (40%) reported partial response of pain. Conclusion: MHB accelerated RT (total dose: 15 Gy) delivered in two consecutive days and two daily fractions is well tolerated.",

keywords = "Aged, Bone Neoplasms, Bone metastases, Combined Modality Therapy, Follow-Up Studies, Humans, Male, Maximum Tolerated Dose, Middle Aged, Palliative therapy, Phase I, Prostate neoplasm, Prostatic Neoplasms, Quality of Life, Radiotherapy, Radiotherapy Dosage, Treatment Outcome, Aged, Bone Neoplasms, Bone metastases, Combined Modality Therapy, Follow-Up Studies, Humans, Male, Maximum Tolerated Dose, Middle Aged, Palliative therapy, Phase I, Prostate neoplasm, Prostatic Neoplasms, Quality of Life, Radiotherapy, Radiotherapy Dosage, Treatment Outcome",

author = "Alice Zamagni and Milly Buwenge and Gabriella Macchia and Giambattista Siepe and Savino Cilla and Francesco Cellini and Alessandra Arcelli and Eleonora Farina and Francesco Deodato and Silvia Cammelli and Morganti, {Alessio G.} and Morganti, {Alessio Giuseppe}",

year = "2019",

doi = "10.21873/anticanres.13699",

language = "English",

volume = "39",

pages = "5065--5069",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research:John G Delinassios, 1st Km Kapandritiou-Kalamou Road, Kapandriti Attiki 19014 Greece:011 30 2 2950 53389, 011 30 2950 52945, EMAIL: journals@iiar-anticancer.org, INTERNET: http://www.iiar-anticancer.org, Fax: 011 30 2 2950 53389, 011 30 2 2950 52945",

}

TY - JOUR

T1 - Accelerated middle half body radiotherapy in bone metastases from prostate cancer: A phase I study (SHARON project)

AU - Zamagni, Alice

AU - Buwenge, Milly

AU - Macchia, Gabriella

AU - Siepe, Giambattista

AU - Cilla, Savino

AU - Cellini, Francesco

AU - Arcelli, Alessandra

AU - Farina, Eleonora

AU - Deodato, Francesco

AU - Cammelli, Silvia

AU - Morganti, Alessio G.

AU - Morganti, Alessio Giuseppe

PY - 2019

Y1 - 2019

N2 - Background/Aim: The primary endpoint of this phase I study was the maximum tolerated dose (MTD) of middle half body (MHB) accelerated radiotherapy (RT) in multiple bone metastatic (BM) prostate cancer (PCa) patients. Patients and Methods: Three step dose escalation [13 Gy (3.25 Gy/fraction), 14 Gy (3.5 Gy/fraction), and 15 Gy (3.75 Gy/fraction)] in three consecutive patient cohorts were planned. RT was delivered in two consecutive days and two daily fractions. Six patients were enrolled in the first two cohorts and 12 in the third cohort. Grade ≥3 toxicity was considered as a dose-limiting toxicity (DLT). Results: Twenty-five patients (median age=71 years, median followup=7.4 months) were enrolled. Defined MTD dose was 15 Gy. Overall pain response rate was 76%: 9 patients (36%) showed complete and 10 patients (40%) reported partial response of pain. Conclusion: MHB accelerated RT (total dose: 15 Gy) delivered in two consecutive days and two daily fractions is well tolerated.

AB - Background/Aim: The primary endpoint of this phase I study was the maximum tolerated dose (MTD) of middle half body (MHB) accelerated radiotherapy (RT) in multiple bone metastatic (BM) prostate cancer (PCa) patients. Patients and Methods: Three step dose escalation [13 Gy (3.25 Gy/fraction), 14 Gy (3.5 Gy/fraction), and 15 Gy (3.75 Gy/fraction)] in three consecutive patient cohorts were planned. RT was delivered in two consecutive days and two daily fractions. Six patients were enrolled in the first two cohorts and 12 in the third cohort. Grade ≥3 toxicity was considered as a dose-limiting toxicity (DLT). Results: Twenty-five patients (median age=71 years, median followup=7.4 months) were enrolled. Defined MTD dose was 15 Gy. Overall pain response rate was 76%: 9 patients (36%) showed complete and 10 patients (40%) reported partial response of pain. Conclusion: MHB accelerated RT (total dose: 15 Gy) delivered in two consecutive days and two daily fractions is well tolerated.

KW - Aged

KW - Bone Neoplasms

KW - Bone metastases

KW - Combined Modality Therapy

KW - Follow-Up Studies

KW - Humans

KW - Male

KW - Maximum Tolerated Dose

KW - Middle Aged

KW - Palliative therapy

KW - Phase I

KW - Prostate neoplasm

KW - Prostatic Neoplasms

KW - Quality of Life

KW - Radiotherapy

KW - Radiotherapy Dosage

KW - Treatment Outcome

KW - Aged

KW - Bone Neoplasms

KW - Bone metastases

KW - Combined Modality Therapy

KW - Follow-Up Studies

KW - Humans

KW - Male

KW - Maximum Tolerated Dose

KW - Middle Aged

KW - Palliative therapy

KW - Phase I

KW - Prostate neoplasm

KW - Prostatic Neoplasms

KW - Quality of Life

KW - Radiotherapy

KW - Radiotherapy Dosage

KW - Treatment Outcome

UR - http://hdl.handle.net/10807/203505

U2 - 10.21873/anticanres.13699

DO - 10.21873/anticanres.13699

M3 - Article

SN - 0250-7005

VL - 39

SP - 5065

EP - 5069

JO - Anticancer Research

JF - Anticancer Research

ER -

Accelerated middle half body radiotherapy in bone metastases from prostate cancer: A phase I study (SHARON project)

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo